Profound Medical to Release Second Quarter 2026 Financial Results on August 6th - Conference Call to Follow
Profound Medical: Autonomous Robotics and Incisionless Surgery to Have Exceptional Presence at SRS2026
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
Profound Medical to Release First Quarter 2026 Financial Results on May 7 - Conference Call to Follow
Incision-Free, MRI-Guided Prostate Treatment with Profound's TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24
Profound Medical to Release Fourth Quarter and Full Year 2025 Financial Results on March 5th - Conference Call to Follow
QIMC Defines Multiple New Hydrogen Hot Zones in Nova Scotia, Reports Stronger Preliminary DDH-26-05 Hydrogen Readings and Triples 2026 Nova Scotia Exploration Program Across a 43-km District-Scale Corridor
